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Background: Flow cytometry is the gold standard for phenotyping and quantifying immune cells. New
technologies have greatly increased our capacity to measure both routine and complex immunophenotypes. The
reporting of immunophenotype data is not consistent in human studies yet it is quite critical for understanding
disease specific changes, responses to immunotherapies, and normal immune homeostasis. Here we examine the
barriers that hinder cross comparisons of flow cytometry data collected from human studies and clinical trials.
Findings: We demonstrate that phenotypes reported as percentages within a cell compartment (i.e. myeloid
derived suppressor cells as a percent of mononuclear cells) without providing data on the parent population may
contribute to misleading conclusions. The enumeration of phenotypes as cell counts (cells/μl) provides a basis to
more accurately compare the relationships among phenotypes. Finally, we provide evidence that density gradient
centrifugation, which eliminates the ability to measure phenotypes as cell counts, can affect the expression of
surface markers and consequently alter the distribution of particular immunophenotypes.
Conclusions: We propose that by measuring immunophenotypes as cell counts from minimally manipulated
samples (whole blood) will improve the reporting of flow data and facilitate more direct comparisons of data across
human studies.
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Introduction
Flow cytometry has become a foundational tool to analyze
the immune system. The emergence of multiparametric
analyses using novel fluorochromes has greatly expanded
our ability to dynamically characterize a broad repertoire
of immunophenotypes. However, careful controls and
methodologies are required to generate reproducible
and scientifically valid data, as was recently highlighted
in a review by Maecker et al. [1]. We have identified
that commonly used approaches for sample prepar-
ation (i.e. density gradient centrifugation) and the stat-
istical analysis resulting from this approach leads to
potentially erroneous data and misinterpretations about
changes in immunophenotypes.
Current standard approaches in research laboratories
rely on density gradient centrifugation and often followed* Correspondence: dietz.allan@mayo.edu
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unless otherwise stated.by cryopreservation. While this step circumvents the
problems of storing whole blood samples, it removes
over 50% of the entire leukocyte population, namely
granulocytes (basophils, eosinophils and neutrophils).
The data derived from density centrifugation-prepared
samples moreover relies on three critical assumptions;
1) that pathologies do not affect the density of cells, 2)
that immune phenotypes are unaffected and 3) that
only granulocytes are eliminated. Despite this technique
being widely used, there is little (if any) supporting data
demonstrating the accuracy of this isolation step nor or
the purity of the isolated population. Perhaps most im-
portantly, this method fails to permit quantification of cell
counts in blood (cells/μl). As clinical flow labs have well
documented, cell counts allow for more accurate and reli-
able comparisons across time and between labs [2-6].
The field of clinical flow cytometry has moved away
from density gradient centrifugation and has benefited
greatly from enumerating immune phenotypes from whole
blood. There is a substantial amount of data reported in
the literature demonstrating that single platform assaysral Ltd. This is an Open Access article distributed under the terms of the Creative
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institutional studies. For example, absolute CD4+ cell
counts in HIV patients has been crucial for defining
HIV/AIDS disease status and is part of the criteria for
treatment decisions. Indeed, the use of flow cytometry
for measuring CD4+ cell counts has become so rou-
tine, that most clinical studies do not report how the
CD4+ cells were quantified [2]. Whitby et al. reported
that the standardization of CD4 enumeration by single
platform method reduced inter-laboratory CV to less
than 5% [5]. In addition to the CD4 assay, the enumer-
ation of CD34+ cells for hematopoietic stem cell trans-
plantation has been another assay that has been very
successful in harmonizing data comparison across institu-
tions. Gratama and colleagues validated a single platform
assay (ISHAGE) for measuring cells/μl and reported inter-
laboratory CVs of about 10% across 36 laboratories [3].
This method was subsequently credited for being a major
factor in reducing the variability of CD34 enumeration in
a nine year follow up study [4]. These examples should
compel us in the research community to include some of
these principles to standardize assays in translational
research.
Another consequence of density based purification of
cells for flow analysis is that immunophenotypes can
only be expressed as a fraction or percentage of a larger
group. This is a very common practice, where the pheno-
type of interest (regulatory T cells or myeloid derived sup-
pressor cells, for example) is reported as a percent of a
larger group (% Tregs = CD4+CD127lowCD25+/CD4+).
Conclusions are drawn regarding the change in percent-
age, with assumptions that the parent or grandparent
population is fixed. For example, the increases in the regu-
latory T cell population reported as a percent of the parent
population (CD4) can change either by increasing the
regulatory T cells and holding the CD4 population con-
stant or by not changing (or even reducing) the regulatory
T cell population and simultaneously reducing the CD4
population to a greater extent. In some cases, the parent
population is represented via the mononuclear cells that
were assumed to be purified during density centrifugation.
While measuring frequencies of subsets is still valuable
and useful for the development of biomarkers associated
with clinical outcomes, reporting the data without add-
itional context (i.e. data regarding the parent/grandparent
population) can often result in an incomplete picture of
the true relationships of one phenotype to another.
Results and discussion
To illustrate the issues with sample collection and in-
complete data reporting, we reanalyzed the data from
several of our published studies in which we have phe-
notyped leukocyte populations by flow cytometry from
human subjects [7-11]. Our samples were analyzed using(freshly isolated) whole blood allowing us to determine
both the number of cells/μl (via single platform bead
indexing) and relative percentages. In our cohort of glio-
blastoma patients (GBM) and healthy volunteer (HV)
controls [8,9], the T cell compartment was decreased
and B cell population was elevated in GBM patients
compared to HV controls when measured as a percent
of lymphocytes (Figure 1A). However, when the popula-
tions were compared using cells/μl only the T cells were
different between GBM and HV groups. This change re-
sulted from specific loss of T cells in GBM patients that
affect the percentage of B cells when expressed as a frac-
tion. In a separate cohort, blood samples from GBM pa-
tients enrolled in clinical trial #NCCTG N027D were
collected at various times before and after treatment
[11]. This trial was initiated to test whether the addition
of temsirolimus (CCI-779) to chemoradiation would im-
prove the responses to treatment versus chemoradiation
alone. We performed immunophenotyping on the treated
GBM patients to assess the effects of the treatment on im-
mune cells and to determine why three patients enrolled
early in the trial developed fatal infection-related toxic-
ities. We measured lymphocyte populations by cell counts
and as percentages of total lymphocytes. This treatment
resulted in profound suppression of T cells, B cells, and
NK cells. Here, we highlight this trial as an example of the
importance of quantifying immune cells in addition to just
measuring their frequency. The levels of NK cells, as mea-
sured by a percent of total lymphocytes, revealed no dif-
ferences at baseline or on treatment compared to HV
controls (Figure 1B). When NK cells were analyzed using
cell counts, there was a reduction in NK cells following
treatment. Again, the disparity between the two measure-
ments was the result of a drop in the lymphocyte com-
partment after GBM patients were treated even as the
ratio of NK cells to total lymphocytes did not change. Al-
though the drop in NK cells likely reflects a general de-
cline in the entire lymphocyte pool, had we measured
these phenotypes from density purified cells, we would
not have detected the profound lymphopenia and thus
concluded that the treatment was not affecting the
lymphocyte compartment. The conclusions drawn from
this scenario could have had severe consequences as it
could have put additional patients on trial at risk for
infection-related toxicities. These examples underscore
the significance of understanding the data within a more
global context. Unifying the context (turning all data into
cells/μl) permits accurate and reliable data analysis. More-
over, accounting for the entire mononuclear compartment
provides a more comprehensive perspective on the entire
immune system. The data can be graphed in a way to
visualize either the entire leukocyte compartment or mono-
nuclear cells. Figure 1C shows the average mononuclear
compartment of 40 healthy volunteers compared to the
Figure 1 The method of data presentation and sample preparation can affect immune phenotype results. A. T cells, B cells, and
lymphocytes were reported as a fraction of a larger population (top graphs) or enumerated by cell counts (cells/μl) (bottom graphs) from
glioblastoma patients (n = 27) and healthy volunteer controls (n = 40). B. NK cells reported as a percentage of lymphocytes or NK cells and
lymphocytes reported per unit of blood for GBM patients at baseline (n = 13), treatment (n = 12) and compared to HV controls C. Measuring
leukocytes per unit of blood allows complete reconstitution of the composition of blood. Pie graphs representing the mononuclear compartment
of healthy volunteers (HV) and glioblastoma patients (GBM) includes CD4+CD3+ T cells (dark blue), CD8+CD3+ T cells (light blue), regulatory T
cells (CD25+CD127loCD4+CD3+, white), CD19+ B cells (green), CD56+CD16+ NK cells (yellow), CD14+HLA-DR+ monocytes (black), and
CD14+HLA-DRlo/neg monocytes (red). D. CD14 and CD16 bivariate plot overlay of CD14+ gated monocytes from cells stained from whole
blood (black) and the same sample with cells stained from density gradient centrifugation (PBMC; red). Comparison of classical (CD14+CD16−) and
intermediate monocyte (CD14+CD16+) populations from ten healthy volunteer blood samples that were either directly stained from whole blood
or stained from PBMCs. All studies were performed under the review and approval of the Mayo Clinic Institutional Review Board. Asterisk
indicates p < 0.05 and ** indicates p < 0.005 by Mann–Whitney test for unpaired samples.
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subsets change in a particular disease setting. Indeed,
our analysis of over 25 GBM patients has demon-
strated that GBM patients are lymphopenic and have
elevated CD14+HLA-DRlo/neg monocytes [8,9]. Enumer-
ation allows comparison of relationships of previouslycompared phenotypes (such as CD4 and CD8 within the
CD3 compartment) as well as relationships previously not
evaluated (such as B cells to NK cells).
We also looked at the consistency of reporting of mye-
loid derived suppressor cells (MDSCs), a heterogeneous
population that is of very high interest. Using PubMed,
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suppressor cells” for the year “2013” (through 10/01/
2013), and found 95 publications of which 13 reported
data on MDSCs in peripheral blood. Of these, 10 of 13
used PBMCs as the source material and only one clearly
measured the MDSC population in cell counts with cor-
responding parent enumeration. The majority reported
MDSCs as a percent of PBMCs with the assumption again,
that the parent population was constant. This is particularly
problematic in leukemias like chronic lymphocytic leukemia,
in which the PBMC compartment is vastly enlarged by can-
cerous B cells and so any reporting of MDSCs as a percent
of PBMCs is rather meaningless. For example, by measuring
cell counts in addition to phenotype frequency (percent of a
parent group), we were able to identify significant clinical
correlations between CD14+HLA-DRlo/neg monocytes, total
monocytes and disease progression in CLL [7]. In other can-
cers where the PBMC compartment is often smaller than
the control group, MDSC reporting is further complicated
by assumptions that granulocytes are completely removed
upon density gradient purification. Raychaudhuri et al. show
that, in their analysis of density gradient purified mono-
nuclear cells from GBM patients, 82% of the MDSC popula-
tion (as defined by CD33+HLA-DR−) were positive for the
granulocytic marker CD15+ [12]. These cells were deemed
neutrophilic MDSCs. However, since granulocytes are typ-
ically classified as CD33+HLA-DR−CD15+, there is an obli-
gation to demonstrate that these cells that escaped density
gradient purification are indeed phenotypically and/or func-
tionally different than regular granulocytes.
In a study that directly compares the values of
MDSCs and how they change with various sample
processing methods, Duffy and colleagues identify that
CD14+HLA-DRlo/neg monocytes (monocytic MDSCs)
are elevated in patients with gastrointestinal cancer [13].
Elevated CD14+HLA-DRlo/neg monocytes were observed
across three different processing methods (cell counts
from whole blood, density gradient purified PBMCs,
and cryopreserved/thawed PBMCs). However, the au-
thors noted that CD14+HLA-DRlo/neg monocyte cell
counts from patients differed between whole blood and
fresh PBMCs by almost 2-fold, and the frequency of CD14
+HLA-DRlo/neg monocytes between cryopreserved PBMCs
and fresh PBMCs was different by 2 fold. As such, the
various processing steps had a large impact on the values
of this cell phenotype. We support these attempts to
understand the effect of sample processing has on the data
and to report the whole data so that the audience can
understand the changes as well.
In order to gain better comprehensive understanding of
immune phenotype data from flow cytometry, we strongly
suggest that, when possible, 1) unfractionated whole blood
be directly stained in a manner that enables measurements
of absolute cell counts and 2) if immunophenotypes are tobe reported as percentages, that quantitative data on the
parent or grandparent population be reported as well. This
will require direct antibody staining of peripheral blood
samples with the addition of counting beads. Most flow
cytometers are capable of analyzing lyse/no wash samples
that utilize fluorescent beads to enumerate cell popula-
tions. Multiple protocols to enumerate peripheral blood
populations are now available [14-16]. If these methods
are followed, the data from flow cytometry can be ana-
lyzed in new and interesting ways. This numerically de-
fined and standardized data will permit bioinformatics
approaches to identify distinct immune profiles among
cancer patients [8]. This method will also permit compari-
sons between immune phenotypes across a spectrum of
disease states. This approach does require laboratories to
stain fresh samples, a situation not always amenable in
multi-institution clinical trials. In these cases and/or when
purifying and cryopreserving PBMCs are the best option, we
recommend that steps are taken, similarly to the study by
Duffy et al. [13], to understand the changes of leukocyte
populations in both control and patient samples resulting
from the purification and cryopreservation methods. For ex-
ample, at least a subset of patients should be phenotyped be-
fore and after the isolation step in order to determine how
the isolation alters the data within a patient pool. We ob-
served for example that after staining whole blood and
PBMCs from 10 healthy volunteers, there was a sizeable in-
crease in the expression of CD16, (mean fluorescence inten-
sity, as shown in the bivariate plot overlay in Figure 1D) that
in turn influenced the reporting of classical (CD14+CD16−),
intermediate (CD14+CD16+) (Figure 1D) and non-classical
monocyte populations (CD14loCD16+) (data not shown).
The increase in CD16 in purified samples resulted in a
higher percentage of intermediate monocytes even as CD14
was relatively unaffected by the processing. This data sug-
gests that there may be markers that are more sensitive to
processing steps and provides another example of how sam-
ple processing impacts the data.
Conclusions
In summary, there is a clear disparity between the data
reported from samples collected using density centrifu-
gation and those without. The inconsistencies of sample
preparation result in data that is difficult (if not impos-
sible) to compare. The manipulation of the blood prior
to flow cytometry and the impact of this step on the
analysis and subsequent reporting of the data must be
carefully reconsidered. Clinical flow cytometry has been
very successful in incorporating whole blood cell enu-
meration assays suitable for multi-institutional studies.
We propose that by incorporating steps to unify data
collection and interpretation, the research data will
have more translational impact to clinical research and
practice.
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